240 related articles for article (PubMed ID: 26495746)
1. Advances in small-molecule drug discovery for triple-negative breast cancer.
Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD
Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746
[TBL] [Abstract][Full Text] [Related]
2. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer.
Islam R; Lam KW
Eur J Med Chem; 2020 Dec; 207():112812. PubMed ID: 32937283
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N; Owusu E; Rivera G; Bandyopadhyay D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
[TBL] [Abstract][Full Text] [Related]
8. Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer.
Zhang J; Zou L; Shi D; Liu J; Zhang J; Zhao R; Wang G; Zhang L; Ouyang L; Liu B
J Med Chem; 2021 Oct; 64(19):14192-14216. PubMed ID: 34605238
[TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.
Liao M; Zhang J; Wang G; Wang L; Liu J; Ouyang L; Liu B
J Med Chem; 2021 Mar; 64(5):2382-2418. PubMed ID: 33650861
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
12. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
14. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
15. A Phenotypic Cell-Binding Screen Identifies a Novel Compound Targeting Triple-Negative Breast Cancer.
Chen L; Long C; Youn J; Lee J
ACS Comb Sci; 2018 Jun; 20(6):330-334. PubMed ID: 29718663
[TBL] [Abstract][Full Text] [Related]
16. Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
Chen L; Long C; Nguyen J; Kumar D; Lee J
Bioorg Med Chem Lett; 2018 Feb; 28(3):420-424. PubMed ID: 29287960
[TBL] [Abstract][Full Text] [Related]
17. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
18. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Gordon V; Banerji S
Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
[TBL] [Abstract][Full Text] [Related]
20. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
